BACKGROUND: Pregnancy may alter protein binding (PB) of highly bound protease inhibitors due to changes in plasma concentrations of albumin and alpha-1 acid glycoprotein (AAG). Small changes in PB can greatly impact the fraction of drug unbound (FU) exerting pharmacological effect. We report lopinavir (LPV) PB during third trimester (antepartum, AP) compared to > or =1.7 weeks postpartum (PP) to determine if FU changes compensate for reduced total concentrations reported previously. METHODS: P1026s enrolled women receiving LPV/ritonavir, soft gel capsules 400/100 mg or 533/133 mg twice daily. LPV FU, albumin and AAG were determined AP and PP. RESULTS: AP/PP samples were available from 29/25 women respectively with all but one woman receiving the same dose AP/PP. LPV FU was increased 18% AP vs. PP (mean 0.96+/-0.16% AP vs. 0.82+/-0.21% PP, P=0.001). Mean protein concentrations were reduced AP (AAG=477 mg/L; albumin=3.28 mg/dL) vs. PP (AAG=1007 mg/L; albumin=3.85 mg/dL) (P<0.0001 for each comparison). AAG concentration correlated with LPV binding. Total LPV concentration did not correlate with LPV FU AP or PP. However, higher LPV concentration PP was associated with reduced PB and higher FU after adjustment for AAG. CONCLUSIONS: LPV FU was higher and AAG lower AP vs. PP. The 18% increase in LPV FU AP is smaller than the reduction in total LPV concentration reported previously and is not of sufficient magnitude to eliminate the need for an increased dose during pregnancy.
BACKGROUND: Pregnancy may alter protein binding (PB) of highly bound protease inhibitors due to changes in plasma concentrations of albumin and alpha-1 acid glycoprotein (AAG). Small changes in PB can greatly impact the fraction of drug unbound (FU) exerting pharmacological effect. We report lopinavir (LPV) PB during third trimester (antepartum, AP) compared to > or =1.7 weeks postpartum (PP) to determine if FU changes compensate for reduced total concentrations reported previously. METHODS: P1026s enrolled women receiving LPV/ritonavir, soft gel capsules 400/100 mg or 533/133 mg twice daily. LPV FU, albumin and AAG were determined AP and PP. RESULTS:AP/PP samples were available from 29/25 women respectively with all but one woman receiving the same dose AP/PP. LPV FU was increased 18% AP vs. PP (mean 0.96+/-0.16% AP vs. 0.82+/-0.21% PP, P=0.001). Mean protein concentrations were reduced AP (AAG=477 mg/L; albumin=3.28 mg/dL) vs. PP (AAG=1007 mg/L; albumin=3.85 mg/dL) (P<0.0001 for each comparison). AAG concentration correlated with LPV binding. Total LPV concentration did not correlate with LPV FU AP or PP. However, higher LPV concentration PP was associated with reduced PB and higher FU after adjustment for AAG. CONCLUSIONS:LPV FU was higher and AAG lower AP vs. PP. The 18% increase in LPV FU AP is smaller than the reduction in total LPV concentration reported previously and is not of sufficient magnitude to eliminate the need for an increased dose during pregnancy.
Authors: Scott G Summerfield; Alexander J Stevens; Leanne Cutler; Maria del Carmen Osuna; Beverley Hammond; Sac-Pham Tang; Ann Hersey; David J Spalding; Phil Jeffrey Journal: J Pharmacol Exp Ther Date: 2005-12-05 Impact factor: 4.030
Authors: T Motoya; L N Thevanayagam; T F Blaschke; S Au; J A Stone; A L Jayewardene; J Chi; F T Aweeka Journal: HIV Med Date: 2006-03 Impact factor: 3.180
Authors: F T Aweeka; C Hu; L Huang; B M Best; A Stek; P Lizak; S K Burchett; J S Read; H Watts; M Mirochnick; E V Capparelli Journal: HIV Med Date: 2014-11-18 Impact factor: 3.180
Authors: Mary F Hebert; Songmao Zheng; Karen Hays; Danny D Shen; Connie L Davis; Jason G Umans; Menachem Miodovnik; Kenneth E Thummel; Thomas R Easterling Journal: Transplantation Date: 2013-04-15 Impact factor: 4.939
Authors: Beverly E Sha; Camlin Tierney; Xin Sun; Alice Stek; Susan E Cohn; Robert W Coombs; Barbara Bastow; Francesca T Aweeka Journal: Jacobs J AIDS HIV Date: 2015-05-16
Authors: Kristine B Patterson; Julie B Dumond; Heather A Prince; Amanda J Jenkins; Kimberly K Scarsi; Ruili Wang; Stephanie Malone; Michael G Hudgens; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Anh Nguyen; Steven Rossi; David Croteau; Brookie M Best; David Clifford; Ann C Collier; Benjamin Gelman; Christina Marra; Justin McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Ronald J Ellis; Igor Grant; Edmund Capparelli; Scott Letendre Journal: J Antimicrob Chemother Date: 2013-01-20 Impact factor: 5.790
Authors: Ahmed Hamed Salem; Aksana Kaefer Jones; Marilia Santini-Oliveira; Graham P Taylor; Kristine B Patterson; Angela M Nilius; Cheri Enders Klein Journal: Antimicrob Agents Chemother Date: 2015-11-02 Impact factor: 5.191